Compare Stocks → Move Your Money Before May 22 (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CGTXNASDAQ:EIGRNASDAQ:JNCENASDAQ:MIRO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$1.95+1.0%$1.93$0.90▼$3.49$76.05M1.63194,601 shs55,055 shsEIGREiger BioPharmaceuticals$4.85$1.10▼$43.35$2.55M1.83103,866 shs137,800 shsJNCEJounce Therapeutics$1.88-2.6%$1.89$0.58▼$5.87$98.94M0.752.46 million shs11.60 million shsMIROMiromatrix Medical$3.39$3.38$0.91▼$4.35$92.95M0.0180,095 shsN/AInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics-3.02%+4.89%+5.46%-19.58%+12.21%EIGREiger BioPharmaceuticals0.00%0.00%-68.06%-70.66%-94.18%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%-2.59%MIROMiromatrix Medical0.00%0.00%0.00%0.00%+171.20%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGTXCognition Therapeutics2.8215 of 5 stars3.53.00.00.02.44.20.0EIGREiger BioPharmaceuticals3.9339 of 5 stars3.55.00.04.20.61.70.0JNCEJounce TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMIROMiromatrix MedicalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGTXCognition Therapeutics3.00Buy$6.67241.88% UpsideEIGREiger BioPharmaceuticals3.00Buy$120.00∞ UpsideJNCEJounce TherapeuticsN/AN/AN/AN/AMIROMiromatrix MedicalN/AN/A$3.00-11.50% DownsideCurrent Analyst RatingsLatest EIGR, JNCE, MIRO, and CGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024CGTXCognition TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/27/2024CGTXCognition TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGTXCognition TherapeuticsN/AN/AN/AN/A$0.76 per shareN/AEIGREiger BioPharmaceuticals$15.77M0.00N/AN/A$37.68 per share0.00JNCEJounce Therapeutics$82M1.21N/AN/A$3.54 per share0.53MIROMiromatrix Medical$958.03K97.02N/AN/A$1.25 per share2.71Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGTXCognition Therapeutics-$25.79M-$0.86N/AN/AN/AN/A-83.48%-63.07%5/2/2024 (Estimated)EIGREiger BioPharmaceuticals-$96.78M-$59.16N/AN/AN/A-590.80%-332.49%-99.77%5/9/2024 (Estimated)JNCEJounce Therapeutics-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/AMIROMiromatrix Medical-$29.96M-$1.14N/A∞N/A-2,861.17%-120.49%-90.70%N/ALatest EIGR, JNCE, MIRO, and CGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023CGTXCognition Therapeutics-$0.38-$0.27+$0.11-$0.27N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGTXCognition TherapeuticsN/AN/AN/AN/AN/AEIGREiger BioPharmaceuticalsN/AN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/AN/AMIROMiromatrix MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGTXCognition TherapeuticsN/A3.373.37EIGREiger BioPharmaceuticalsN/A3.313.24JNCEJounce TherapeuticsN/A8.378.37MIROMiromatrix Medical0.023.463.46OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGTXCognition Therapeutics43.35%EIGREiger BioPharmaceuticals62.46%JNCEJounce Therapeutics80.66%MIROMiromatrix Medical29.38%Insider OwnershipCompanyInsider OwnershipCGTXCognition Therapeutics23.80%EIGREiger BioPharmaceuticals4.22%JNCEJounce Therapeutics6.92%MIROMiromatrix Medical5.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCGTXCognition Therapeutics2539.00 million29.72 millionNot OptionableEIGREiger BioPharmaceuticals561.48 million1.42 millionOptionableJNCEJounce Therapeutics13752.63 million48.99 millionOptionableMIROMiromatrix Medical7627.42 million25.99 millionOptionableEIGR, JNCE, MIRO, and CGTX HeadlinesSourceHeadlineWalter Reed Army Medical Centermilitary.com - March 2 at 8:07 PMQ4 2023 United Therapeutics Corp Earnings Calluk.finance.yahoo.com - February 22 at 1:24 AMSouthwest Virginia scientists are gene-editing pigs for human transplantscardinalnews.org - December 19 at 9:31 AMBest Stocks to Buy Right Nowbenzinga.com - November 22 at 6:57 PMMiromatrix Holder Says It Omitted United Therapeutics Deal Infonews.bloomberglaw.com - November 16 at 7:25 PMMiromatrix Medical GAAP EPS of -$0.24, revenue of $11.17Mmsn.com - November 15 at 1:53 PMMiromatrix Reports Third Quarter 2023 Resultsfinance.yahoo.com - November 14 at 8:27 PMMiromatrix Medical climbs 225% following $140m United Therapeutics bidproactiveinvestors.com - October 31 at 10:31 PMUnited Therapeutics agrees to buy Miromatrix Medicalmsn.com - October 31 at 10:31 PMUnited Therapeutics looks to hog bioengineered organ R&D with $91M Miromatrix buyfiercebiotech.com - October 31 at 12:30 PMMiromatrix Medical Shares Triple After United Therapeutics Offermarketwatch.com - October 31 at 12:30 PMUnited Therapeutics buying Miromatrix for up to $140Mbioworld.com - October 30 at 8:55 PMEden Prairie biotech company Miromatrix Medical sells for $91Mstartribune.com - October 30 at 10:48 AMUnited Therapeutics to buy Miromatrix Medical for $3.25 per sharemsn.com - October 30 at 10:48 AMWhy Is Miromatrix Medical (MIRO) Stock Up 235% Today?investorplace.com - October 30 at 9:13 AMMiromatrix to Present at the 2023 ISODP Organ Donation Congressfinance.yahoo.com - October 11 at 7:34 PMMiromatrix CEO Jeff Ross to Present at the 2023 Cell & Gene Meeting on the Mesafinance.yahoo.com - October 5 at 6:16 PMSeveral Insiders Invested In Miromatrix Medical Flagging Positive Newsfinance.yahoo.com - September 10 at 5:39 PMMiromatrix Announces Participation in the ARM Tissue Engineering and Therapeutics Workshopfinance.yahoo.com - September 5 at 4:52 PMMiromatrix Medical Inc. (NASDAQ:MIRO) Q2 2023 Earnings Call Transcriptfinance.yahoo.com - August 21 at 5:29 PMMiromatrix Medical Inc.: Miromatrix Reports Second Quarter 2023 Results and Provides Corporate Updatefinanznachrichten.de - August 15 at 4:21 PMMiromatrix Medical GAAP EPS of -$0.24msn.com - August 15 at 4:21 PMCraig-Hallum Keeps Their Buy Rating on Miromatrix Medical (MIRO)markets.businessinsider.com - August 15 at 4:21 PMQ2 2023 Miromatrix Medical Inc Earnings Callfinance.yahoo.com - August 15 at 9:47 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCognition TherapeuticsNASDAQ:CGTXCognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.Eiger BioPharmaceuticalsNASDAQ:EIGREiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.Miromatrix MedicalNASDAQ:MIROMiromatrix Medical Inc., a life sciences company, develops a novel technology for bioengineering fully transplantable organs. The company's proprietary technology is a platform that uses a two-step method of decellularization and recellularization designed to remove the porcine cells from the organs obtained from pigs and replace them with unmodified human cells. It has collaborations with Baxter, CareDx, The Mayo Clinic, Mount Sinai Hospital, and The Texas Heart Institute. The company was formerly known as TayTech, Inc. Miromatrix Medical Inc. was incorporated in 2009 and is headquartered in Eden Prairie, Minnesota. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.